Biotec Services International completes its rebrand into PCI Group

PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has today rebranded as part of the PCI group.

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has today rebranded as part of the PCI group.

This rebrand brings together the expertise of two world class organizations and significantly expands PCI's capability to deliver an integrated pharmaceutical service for global studies of investigational medicinal products.

The broad range of services includes manufacturing, packaging and labeling, QP and GMP consultancy, global distribution and returned drug management, as well as consultant services for optimal clinical package design, global logistics planning and depot management over a wide range of temperatures from controlled ambient to -196 degrees C, a service for which Biotec is known across the globe.

Dr Fiona Withey, Managing Director, UK Clinical Services, stated, "The rebranding of Biotec demonstrates to the global pharmaceutical community that by joining the PCI group we are able to offer a significantly increased global capacity to deliver a worldwide offering to our clients across a wider range of services, while staying true to our core values of expertise, customer service, efficiency and flexibility. We are very excited about the investments PCI has undertaken of late, the acquisition of Biotec and Penn Pharma along with the construction of a new North American Storage, Distribution and Returns Management site, increases the breadth of the PCI service offering and provides our clients significant opportunity to engage with a truly global pharmaceutical services organization."

Biotec recently announced the completion of an expansion to its Bridgend facilities. This development significantly expands the footprint of its clinical trial packaging and distribution services, as well as its Cold Chain expertise solutions ‹ supporting medicines from +25 degrees C down to -196 degrees C. The enhanced Bridgend facilities are an important part of PCI's network of sites encompassing bothEurope and North America, providing clinical and commercial medicines to over 100 countries globally.

>> For more information, click here

 

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report